| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44000478 | HTLV-1 | ENSG00000175868.14 | protein_coding | CALCB | No | No | 797 | P10092 |
| TVIS44026562 | HTLV-1 | ENSG00000175868.14 | protein_coding | CALCB | No | No | 797 | P10092 |
| TVIS44026563 | HTLV-1 | ENSG00000175868.14 | protein_coding | CALCB | No | No | 797 | P10092 |
| TVIS44026564 | HTLV-1 | ENSG00000175868.14 | protein_coding | CALCB | No | No | 797 | P10092 |
| TVIS44032160 | HTLV-1 | ENSG00000175868.14 | protein_coding | CALCB | No | No | 797 | P10092 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CALCB |
|---|---|
| DrugBank ID | DB14040 |
| Drug Name | Eptinezumab |
| Target ID | BE0002370 |
| UniProt ID | P10092 |
| Regulation Type | binder |
| PubMed IDs | 25297013 |
| Citations | Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
